<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230612058462N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-09</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of vaginal magnesium sulfate in preparing the cervix before labor induction</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of vaginal magnesium sulfate in preparing the cervix before labor induction</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>104</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70792</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly assigned to two groups of 52 people, A and B, using random assignment computer software, and the number of groups and samples are recorded in this software, and people are randomly assigned to two groups. The randomization list will be determined by the statistician, Blinding description: The study will be conducted in a triple-blind manner. Completely similar vials containing normal saline (placebo or placebo) and magnesium sulfate will be used without drug labels. These vials will be labeled with an A or B code by another research colleague. They will be separated from each other and the patient and the examiner and the researcher and the analyst will be completely unaware of its nature.</study_design>
      <phase>3</phase>
      <hc_freetext>The effect of vaginal magnesium sulfate in preparing the cervix before induction of labor.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Completely similar vials containing normal saline ( placebo) and 50% magnesium sulfate from Shahid Ghazi Pharmaceutical Company of Tabriz, which are without drug labels, will be used. These vials will be labeled with an A or B code by another research colleague They will be separated, and the patient and the examiner, the researcher and the analyst will be completely unaware of its nature. In the initial examination, Bishop's score will be determined for the patient, then cotton soaked with 5 cc of vial A or B will be placed in the patient's cervix. 3 hours later, the patient will be examined again and the secondary Bishop score will be determined. Also, by entering the relevant code in the partograph form, the duration of labor and the active phase of labor were measured in each patient. Intervention 2: Control group: : Completely similar vials containing normal saline (placebo) and 50% magnesium sulfate from Shahid Ghazi Pharmaceutical Company of Tabriz, which are without drug labels, will be used. These vials will be labeled with an A or B code by another research colleague They will be separated, and the patient and the examiner, the researcher and the analyst will be completely unaware of its nature. In the initial examination, Bishop's score will be determined for the patient, then cotton soaked with 5 cc of vial A or B will be placed in the patient's cervix. 3 hours later, the patient will be examined again and the secondary Bishop score will be determined. Also, by entering the relevant code in the partograph form, the duration of labor and the active phase of labor were measured in each patient.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data related to the main outcome of the study

When:
1 year after the publication of the article

To whom:
Medical students and gynecologists

Conditions:
Request through personal email - use for academic research

Where to obtain:
The applicant should send an email to the research unit of the university, after explaining the working method, the necessary information will be sent

How to obtain:
Email your request to the research unit of the university and give a brief explanation about your work method or the details required from this study so that the details will be sent via email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyede ayeh musavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO. 131 ،East Torbat Ave، saadi Qii</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۶۱۳۶۶۸۵۴۷۷</zip>
        <telephone>+98 61 3337 4753</telephone>
        <email>S.r.musavi88@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyede ayeh musavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO. 131 ،East Torbat Ave، saadi Qii</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۶۱۳۶۶۸۵۴۷۷</zip>
        <telephone>+98 61 3337 4753</telephone>
        <email>S.r.musavi88@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women 18_35 years
BMI :19/8 _30
Gestational age 34_42 week by first trimester sonograghy
A single alive fetus with cephalic presentation and 2500_4000 gr by sonograghy
Having a Indication to labor induction</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having indications for cesarean section
Lack of consent to participate in the study
Having a history of cesarean section</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Completely similar vials containing normal saline ( placebo) and 50% magnesium sulfate from Shahid Ghazi Pharmaceutical Company of Tabriz, which are without drug labels, will be used. These vials will be labeled with an A or B code by another research colleague They will be separated, and the patient and the examiner, the researcher and the analyst will be completely unaware of its nature. In the initial examination, Bishop's score will be determined for the patient, then cotton soaked with 5 cc of vial A or B will be placed in the patient's cervix. 3 hours later, the patient will be examined again and the secondary Bishop score will be determined. Also, by entering the relevant code in the partograph form, the duration of labor and the active phase of labor were measured in each patient.</i_keyword>
      <i_keyword>Control group: : Completely similar vials containing normal saline (placebo) and 50% magnesium sulfate from Shahid Ghazi Pharmaceutical Company of Tabriz, which are without drug labels, will be used. These vials will be labeled with an A or B code by another research colleague They will be separated, and the patient and the examiner, the researcher and the analyst will be completely unaware of its nature. In the initial examination, Bishop's score will be determined for the patient, then cotton soaked with 5 cc of vial A or B will be placed in the patient's cervix. 3 hours later, the patient will be examined again and the secondary Bishop score will be determined. Also, by entering the relevant code in the partograph form, the duration of labor and the active phase of labor were measured in each patient.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bishop score. Timepoint: Before intervention and after 3 hours. Method of measurement: According to Bishop score.</prim_outcome>
      <prim_outcome>Total time of vaginal delivery. Timepoint: Since start labor induction till vaginal delivery. Method of measurement: Clock.</prim_outcome>
      <prim_outcome>Time of active phase of labor. Timepoint: Since cervix dilatation 4cm till vaginal delivery. Method of measurement: Clock.</prim_outcome>
      <prim_outcome>Type of delivery. Timepoint: After delivery. Method of measurement: View and Record file.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-25</approval_date>
        <contact_name>Ethic committee of Ahvaz University of medical science</contact_name>
        <contact_address>Ahvaz - Golestan - Koi Saadi - East Torbat Street - Plate 131 Ahwaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
